In vitro investigation on the impact of the surface-active excipients Cremophor EL, Tween 80 and Solutol HS 15 on the metabolism of midazolam

Biopharmaceutics and Drug Disposition

Volumn 25, Issue 1, 2004, Pages 37-49

  Bravo González, Robert C B ^a   Huwyler, Jörg ^a   Boess, Franziska ^a   Walter, Isabelle ^a   Bittner, Beate ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Cremophor EL; Hepatocytes; Intrinsic clearance; Midazolam; Solutol HS 15; Tween 80

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARBOXYFLUORESCEIN; CHOLESTEROL; CREMOPHOR; CYTOCHROME P450 3A; EXCIPIENT; LACTATE DEHYDROGENASE; LIPOSOME; MIDAZOLAM; NONIONIC SURFACTANT; PHOSPHATIDYLCHOLINE; POLYSORBATE 80; SOLUTOL HS 15;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DRUG CLEARANCE; DRUG METABOLISM; ENZYME INHIBITION; ENZYME RELEASE; IN VITRO STUDY; INCUBATION TIME; LIVER CELL; LIVER MICROSOME; MALE; MICROSCOPY; MOLECULAR INTERACTION; NONHUMAN; RAT;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CELL SURVIVAL; CELLS, CULTURED; CULTURE MEDIA; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; EXCIPIENTS; GLYCEROL; HEPATOCYTES; MALE; MEMBRANE PROTEINS; MICROSOMES, LIVER; MIDAZOLAM; POLYETHYLENE GLYCOLS; POLYSORBATES; RATS; RATS, WISTAR; STEARIC ACIDS; SURFACE-ACTIVE AGENTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0742324810     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.383     Document Type: Article

References (51)

1. Bittner B, Mountfield RJ. Intravenous administration of poorly soluble new drug entities (NDEs) in early drug discovery: The potential impact of the formulation on pharmacokinetic parameters. Curr Opin Drug Disc Dev 2001; 5: 59-71.
2. Onetto N, Dougan M, Hellmann S, et al. Safety profile. In Paclitaxel in Cancer Treatment, McGuire WP, Rowinsky EK (eds). Marcel Dekker: New York, 1995; 21-149.
3. Schuurhuis GJ, Broxterman HJ, Pinedo HM, et al. The polyoxyethylene castor oil modifies multidrug resistance. Br J Cancer 1990; 62: 591-594.
4. Woodcock DM, Linsenmeyer ME, Chojnowski G, et al. Reversal of multidrug resistance by surfactants. Br J Cancer 1992; 66: 62-68.
5. Chong ASF, Markham PN, Gebel HM, Bines SD, Coon JS. Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells. Cancer Immunol Immunother 1993; 36: 133-139.
6. Buckingham LE, Balasubramanian M, Emanuele RM, Clodfelter KE, Coon JS. Comparison of Solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents. Int J Cancer 1995; 62: 436-442.
7. Kongshaug M, Cheng LS, Moan J, Rimington C. Interaction of Cremophor EL with human plasma. Int J Biochem 1991; 23: 473-478.
8. Sykes E, Woodburn K, Decker D, Kessel D. Effects of Cremophor EL on distribution of taxol to serum lipoproteins. Br J Cancer 1994; 70: 401-404.
9. Woodburn K, Sykes E, Kessel D. Interactions of Solutol HS 15 and Cremophor EL with plasma lipoproteins. Int J Biochem Cell Biol 1995; 27: 693-699.
10. Van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 2001; 19: 125-141.
11. Woollett AM, Morton CG, Bishop JF. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. Natl Cancer Inst 1996; 88: 1297-1301.
12. Sparreboom A, Verweij J, van der Burg MEL, et al. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res 1998; 4: 1937-1942.
13. Van Tellingen O, Beijnen JH, Verweij J, Scherrenburg EJ, Nooijen WJ, Sparreboom A. Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin Cancer Res 1999; 5: 911-922.
14. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 1996; 56: 2112-2115.
15. Sparreboom A, Verweij J, Van Zuylen L, Karlsson MO. A pharmacokinetic model for micellar encapsulation of paclitaxel in Cremophor EL. Proc Am Assoc Cancer Res 2000; 41: 522.
16. Knemeyer I, Wientjes MG, Au JLS. Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother Pharmacol 1999; 44: 241-248.
17. Van Tellingen O, Huizing MT, Nannan Panday VR, Schellens JHM, Nooijen WJ, Beijnen JH. Cremophor EL causes (pseudo) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 1999; 81: 330-335.
18. Webster LK, Cosson EJ, Stokes KH, Millward MJ. Effect of the paclitaxel vehicle, Cremophor EL, on the pharmaco-kinetics of doxorubicin and doxorubicinol in mice. Br J Cancer 1996, 73: 522-524.
19. Millward MJ, Webster LK, Rischin D, et al. Phase I trial of Cremophor EL with bolus doxorubicin. Clin Cancer Res 1998; 4: 2321-2329.
20. Colombo T, Parisi I, Zucchetti M, Sessa C, Goldhirsch A, D'Incalci M. Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin. Ann Oncol 1999; 10: 391-395.
21. Ellis AG, Crinis NA, Webster LK. Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. Cancer Chemother Pharmacol 1996; 38: 81-87.
22. Woodburn K, Chang CK, Lee S, Henderson B, Kessel D. Biodistribution and PIDT efficacy of a ketochlorin photosensitizer as a function of the delivery vehicle. Photochem Photobiol 1994; 60: 154-159.
23. Kurlansky PA, Sadeghi AM, Michler RE, et al. Role of the carrier solution in cyclosporine pharmacokinetics in the baboon. J Heart Transplant 1986; 5: 312-316.
24. Kay NH, Uppington J, Sear JW, Douglas EJ, Cockshott ID. Pharmacokinetics of propofol (Diprivan) as an induction agent. Postgrad Med 1985; 61: 55-57.
25. Azmin MN, Stuart JFB, Florence AT. The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80. Cancer Chemother Pharmacol 1985; 14: 238-242.
26. Jacqz-Aigrain E, Daoud P, Burtin P, Desplanques L, Beaufils F. Placebo-controlled trial of midazolam sedation in mechanically ventilated newborn babies. Lancet 1994; 344: 646-650.
27. Burtin P, Jacqz-Aigrain E, Girard P, et al. Population pharmacokinetics of midazolam in neonates. Clin Pharmcol Ther 1994; 56: 615-625.
28. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989; 36: 89-96.
29. Wandel C, Bocker R, Bohrer H, Browne A, Rugheimer E, Martin E. Midazolam is metabolised by at least three different cytochrome P450 enzymes. Br J Anaesth 1994; 73: 658-661.
30. Ghosal A, Satoh H, Thomas PE, Bush E, Moore D. Inhibition kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab Dispos 1996; 24: 940-947.
31. Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999; 16: 408-414.
32. Lavé T, Dupin S, Schmitt C, Valles B, Ubaud G, Chou RC. The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm Res 1997; 14: 152-155.
33. Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol 1976; 13: 29-83.
34. Ubeaud G, Schiller CD, Hurbin F, Jaeck D, Coassolo P. Comparison of the stability of some major cytochrome P450 and conjugation reactions in rat, dog and human hepatocyte monolayers. Eur J Drug Metab Pharmacokinet 2001; 26: 37-45.
35. Ubeaud G, Schmitt C, Jaeck D, Lavé T, Coassolo P. Bosentan, a new endothelin receptor antagonist: prediction of the systemic plasma clearance in man from combined in vivo and in vitro data. Xenobiotica 1995; 25: 1381-1390.
36. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and non-specific binding to microsomes. Drug Metab Disp 1999; 27: 1350-1359.
37. Turman MA, Mathews A. A simple luciferase assay to measure ATP levels in small numbers of cells using a fluorescent plate reader. In vitro Cell Dev Biol Animal 1996; 32: 1-4.
38. Taylor AL, Kudlow BA, Marrs KL, Gruenert D, Guggino WB, Schwiebert EM. Bioluminescence detection of ATP release mechanisms in epithelia. Am J Physiol Cell Physiol 1998; 44: 1391-1406.
39. Blume G, Cevc G. Liposomes for the sustained drug release in vivo. Biochim Biophys Acta 1990; 1029: 61-70.
40. Kamm W, Jonczyk A, Jung T, Luckenbach G, Raddatz P, Kissel T. Evaluation of absorption enhancement for a potent cyclopeptidic ανβ3-anatgonist in a human intestinal cell line (Caco-2). Eur J Pharm Sci 2000; 10: 205-214.
41. Brandhoest D, Brandhoest H, Hering BJ, Federlin K, Bretzel RG. Large variability of the intracellular ATP content of human islets isolated from different donors. J Mol Med 1999; 77: 93-95.
42. Lo YL, Shu CY, Huang JD. Comparison of effects of surfactants with other MDR reversing agents on intracellular uptake of epirubicin in caco-2 cell line. Anticancer Res 1998; 18: 3005-3010.
43. Yu L, Bridgers A, Polli J, et al. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res 1999; 16: 1812-1817.
44. Aránzazu Partearroyo M, Ostolaza H, Goni FM, Barberá Guillem E. Surfactant-induced cell toxicity and cell lysis. A study using B16 melanoma cells. Biochem Pharmacol 1990; 40: 1323-1328.
45. Xia WJ, Onyuksel H. Mechanistic studies of surfactant-induced membrane permeability enhancement. Pharm Res 2000; 17: 612-618.
46. Malik SN, Canaham DH, Gouda MW. Effect of surfactants on absorption through membranes III: effects of dioctyl sodium sulfosuccinate and poloxalene on absorption of a poorly absorbable drug, phenolsulfonphthalein, in rats. J Pharm Sci 1975; 64: 987-990.
47. Nerurkar MM, Ho NF, Burton PS, Vidmar TJ, Borchardt RT. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in caco-2 cells. J Pharm Sci 1997; 86: 813-821.
48. Poelma FG, Breäs R, Tukker JJ, Crommelin DJ. Intestinal absorption of drugs. The influence of mixed micelles on the disappearance kinetics of drugs from the small intestine of the rat. J Pharm Pharmacol 1991; 43: 317-324.
49. Wade A, Weller PJ. Handbook of Pharmaceutical Excipients, 2nd edition. Pharmaceutical Press: London, 1994.
50. Bittner B, Guenzi A, Fullhardt P, Zuercher G, Bravo González RC, Mountfield RJ. Improvement of the oral bioavailability of colchicine in male Wistar rats by co-administration of the surface-active formulation ingredients Solutol HS 15 and Vitamin E-TPGS. Arnzeimittelforsch/Drug Res 2002; 52: 684-688.
51. Mountfield R, Senepin S, Schleimer M, Walter I, Bittner B. The potential inhibitory effect of formulation ingredients on intestinal cytochrome P450. Int J Pharm 2000; 211: 89-92.